# An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

> **NCT04395989** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 139 (actual)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** A1: Pyrotinib with nab-paclitaxel
- **DRUG:** A2: nab-paclitaxel
- **DRUG:** B1: everolimus with nab-paclitaxel
- **DRUG:** B2: nab-paclitaxel
- **DRUG:** C1: PD-1 with nab-paclitaxel and famitinib
- **DRUG:** C2: nab-paclitaxel
- **DRUG:** D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
- **DRUG:** D2: nab-paclitaxel, with maintenance of capecitabine
- **DRUG:** E1: everolimus with nab-paclitaxel
- **DRUG:** E2: nab-paclitaxel

## Key facts

- **NCT ID:** NCT04395989
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-28
- **Primary completion:** 2023-05-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04395989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04395989, "An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04395989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*